Cinven's AMCo widens pricing for £984m dividend recap loan
Amdipharm Mercury (AMCo), the UK generic pharmaceuticals group owned by Cinven, has widened pricing on its £984m refinancing and recapitalisation loan, as investors worry about a £420m dividend for its owners.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: